A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia.

IF 2.1 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Annals of Thoracic Medicine Pub Date : 2023-04-01 Epub Date: 2023-04-25 DOI:10.4103/atm.atm_264_22

Mohammed Ayaz Khan, Basma Al Ghamdi, Mohammed Alhamadi, Rajkumar Rajendram, Sami Alyami, Majed Al-Gamedi, Abdullah Al-Harbi, Hamdan Al-Jahdali

{"title":"A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia.","authors":"Mohammed Ayaz Khan, Basma Al Ghamdi, Mohammed Alhamadi, Rajkumar Rajendram, Sami Alyami, Majed Al-Gamedi, Abdullah Al-Harbi, Hamdan Al-Jahdali","doi":"10.4103/atm.atm_264_22","DOIUrl":null,"url":null,"abstract":"Background: The prognosis of idiopathic pulmonary fibrosis (IPF) can be predicted by the gender, age, and physiology (GAP) index. However, antifibrotic therapy (i.e., nintedanib and pirfenidone) may improve survival.Aims: This study aimed to compare the outcomes of antifibrotic-treated IPF with the survival predicted by the GAP index.Methods: A retrospective cohort study was conducted from March 2014 to January 2020. The electronic health-care records of all IPF patients treated with nintedanib or pirfenidone were reviewed. Besides standard demographic and mortality data, the variables required to calculate the GAP index were also extracted.Results: Eighty-one patients (male 55, 68%; age 71.4 ± 10.2 years) with IPF received antifibrotic therapy (nintedanib 44.4%; pirfenidone 55.6%; mean follow-up 35 ± 16.5 months). Cumulative mortality (whole cohort 3 years 12%; 4 years 26%; 5 years 33%) was significantly less than predicted by the GAP index.Conclusions: The survival of antifibrotic-treated IPF is better than predicted by the GAP index. Novel systems for prognostication are required. The survival benefit from pirfenidone and nintedanib seem similar overall.","PeriodicalId":50760,"journal":{"name":"Annals of Thoracic Medicine","volume":"18 2","pages":"79-85"},"PeriodicalIF":2.1000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/d4/ATM-18-79.PMC10263079.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Thoracic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/atm.atm_264_22","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The prognosis of idiopathic pulmonary fibrosis (IPF) can be predicted by the gender, age, and physiology (GAP) index. However, antifibrotic therapy (i.e., nintedanib and pirfenidone) may improve survival.

Aims: This study aimed to compare the outcomes of antifibrotic-treated IPF with the survival predicted by the GAP index.

Methods: A retrospective cohort study was conducted from March 2014 to January 2020. The electronic health-care records of all IPF patients treated with nintedanib or pirfenidone were reviewed. Besides standard demographic and mortality data, the variables required to calculate the GAP index were also extracted.

Results: Eighty-one patients (male 55, 68%; age 71.4 ± 10.2 years) with IPF received antifibrotic therapy (nintedanib 44.4%; pirfenidone 55.6%; mean follow-up 35 ± 16.5 months). Cumulative mortality (whole cohort 3 years 12%; 4 years 26%; 5 years 33%) was significantly less than predicted by the GAP index.

Conclusions: The survival of antifibrotic-treated IPF is better than predicted by the GAP index. Novel systems for prognostication are required. The survival benefit from pirfenidone and nintedanib seem similar overall.

Abstract Image

查看原文本刊更多论文

沙特阿拉伯抗纤维化治疗背景下特发性肺纤维化的生存分析。

背景：特发性肺纤维化（IPF）的预后可以通过性别、年龄和生理学（GAP）指数来预测。然而，抗纤维化治疗（即宁替达尼和吡非尼酮）可以提高生存率。目的：本研究旨在比较抗纤维化治疗的IPF的结果与GAP指数预测的生存率。方法：2014年3月至2020年1月进行回顾性队列研究。回顾了所有接受尼替达尼或吡非尼酮治疗的IPF患者的电子医疗记录。除了标准的人口统计和死亡率数据外，还提取了计算GAP指数所需的变量。结果：81例IPF患者（男性55.68%；年龄71.4±10.2岁）接受了抗纤维化治疗（尼替达尼44.4%；吡非尼酮55.6%；平均随访35±16.5个月）。累计死亡率（整个队列3年12%；4年26%；5年33%）显著低于GAP指数预测的死亡率。结论：经抗纤维化治疗的IPF的生存率高于GAP指数预测的生存率。需要新的预测系统。吡非尼酮和宁替达尼的生存益处似乎总体相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Thoracic Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-RESPIRATORY SYSTEM

CiteScore

4.10

自引率

4.30%

发文量

审稿时长

>12 weeks

期刊介绍： The journal will cover studies related to multidisciplinary specialties of chest medicine, such as adult and pediatrics pulmonology, thoracic surgery, critical care medicine, respiratory care, transplantation, sleep medicine, related basic medical sciences, and more. The journal also features basic science, special reports, case reports, board review , and more. Editorials and communications to the editor that explore controversial issues and encourage further discussion by physicians dealing with chest medicine.